Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5349530 | 0.98 | TBXAS1 (0.61) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL933853 | 0.91 | TBXAS1 (0.68) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL4304368 | 0.89 | TBXAS1 (0.76) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL18248629 | 0.88 | TBXAS1 (0.77) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL10772829 | 0.88 | TBXAS1 (0.77) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL14959999 | 0.88 | TBXAS1 (0.77) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL27939457 | 0.85 | TBXAS1 (0.64) | RECQLTBXAS1CHRNA7CYP2A6NAPRT | |
| SCHEMBL333061 | 0.83 | TBXAS1 (0.78) | TBXAS1CHRNA7NAPRTCYP1A2CYP3A4 | |
| SCHEMBL29403620 | 0.83 | TBXAS1 (0.78) | TBXAS1CHRNA7NAPRTCYP1A2CYP3A4 | |
| Niacinamide SCHEMBL5309275 | 0.82 | F7 (0.65) | RECQLTBXAS1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699005-A | 3- (carboxy ethyl) -8- amino -2- oxo -1,3- aza-spiros-[4.5]Decane derivative | 格吕伦塔尔有限公司 | 2018-10-23 | — | — | CN | claimed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| EP-3089969-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 | Elexopharm GmbH (DE) | 2016-11-09 | — | — | EP | claimed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | claimed |
| CN-103687860-B | As P2X7Heterocyclic amide derivatives of receptor antagonists | 埃科特莱茵药品有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-103687860-A | As P2X7Heterocyclic amide derivatives of receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2014-03-26 | — | — | CN | claimed |
| JP-4607319-B2 | — | — | 2011-01-05 | — | — | JP | claimed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| US-7309701-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-12-18 | — | — | US | claimed |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-09-09 | — | — | US | claimed |
| WO-2004046130-A1 | PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | WO | claimed |
| WO-2004046117-A1 | PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-03 | — | — | WO | claimed |
| EP-1377589-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-01-07 | — | — | EP | claimed |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | PURDUE RESEARCH FOUNDATION | 2003-02-13 | — | — | US | claimed |
| WO-2002062804-A1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2002-08-15 | — | — | WO | claimed |
| JP-2002512190-A | — | — | 2002-04-23 | — | — | JP | claimed |
| WO-2002030466-A2 | PHARMACEUTICAL APPLICATIONS OF HYDROTROPIC AGENTS, POLYMERS THEREOF, AND HYDROGELS THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | claimed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | HSD17B1, HSD17B2, HSD17B3 | RECQL 868/4885TBXAS1 613/4885CHRNA7 2827/4885 |
| US-20040176377-A1 | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | ADRA2C, ADRA1A, ADRA1B | RECQL 690/4885TBXAS1 333/4885CHRNA7 553/4885 |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | HMGB2, HTT, ABCG2 | RECQL 842/4885TBXAS1 673/4885CHRNA7 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.